ALS is disease of selective motor neuronal loss in the brain and spinal cord for voluntary muscles with median age of symptoms starting at 55.

High levels of Oxidative Stress/Calcium, ER stress and Mitochondrial Dysfunction found in All variants including SOD1 patients.

Loss of motor results in muscle wasting, eventually respiratory muscle loss and subsequently death within ~3-years upon diagnosis.

SOD1 model treatment 8 weeks, once-per-day orally with a ultra-low dose of MP101 at 0.5mg/kg, a human equivalent dose of 2mg/day.

Our Data Shows:

Improved motor function and strength versus placebo.

Durable improvement over time versus placebo.

Preservation of neuromuscular junction similar to Wild-type mice.